Growth Hormone Secretagogues: Sermorelin, Ipamorelin & CJC-1295
A comprehensive research reference on GH secretagogues — covering GHRH receptor pharmacology, GHSR agonism, DAC modification, pulsatile GH release, and the hypothalamic-pituitary-somatotropic axis.
The Hypothalamic-Pituitary-Somatotropic Axis
Growth hormone (GH) secretion is regulated by a complex neuroendocrine feedback system centered on the hypothalamic-pituitary-somatotropic (HPS) axis. The hypothalamus releases growth hormone-releasing hormone (GHRH) in a pulsatile pattern, which stimulates anterior pituitary somatotrophs to synthesize and secrete GH. Somatostatin (SRIF), also released by the hypothalamus, acts as the primary inhibitory counterpart, suppressing GH release between pulses. GH then acts on peripheral tissues to stimulate IGF-1 production, which feeds back to suppress both GHRH and GH secretion.
Growth hormone secretagogues (GHS) are a class of compounds that stimulate GH release through two distinct receptor-mediated mechanisms: GHRH receptor (GHRHR) agonism, which mimics the action of endogenous GHRH; and GH secretagogue receptor (GHSR) agonism, which activates the ghrelin receptor pathway independently of GHRH. Unlike exogenous GH administration, secretagogues work within the body's natural feedback loops, making them valuable research tools for studying the HPS axis without fully bypassing endogenous regulation.
Sermorelin: GHRH Receptor Agonism
Sermorelin is a 29-amino acid synthetic analog of growth hormone-releasing hormone, representing the shortest fully active fragment of the native 44-amino acid GHRH molecule. The first 29 amino acids of GHRH contain the complete receptor-binding domain, making sermorelin a minimal but fully functional GHRHR agonist. It binds directly to GHRH receptors on pituitary somatotrophs, activating the adenylate cyclase-cAMP signaling cascade to stimulate GH synthesis and secretion.
Research applications of sermorelin include studying age-related GH decline and pituitary responsiveness, the downstream effects of GH pulses on IGF-1 production, the relationship between GHRH receptor density and GH secretory capacity, and the effects of sustained GHRHR stimulation on somatotroph function. Sermorelin has a relatively short half-life of approximately 10–20 minutes, making it useful for studying acute pulsatile GH release rather than sustained elevation.
Ipamorelin: Selective GHSR Agonism
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist at the GH secretagogue receptor (GHSR-1a), also known as the ghrelin receptor. It was developed specifically to address the selectivity limitations of earlier GHSR agonists like GHRP-6, which stimulate GH release but also significantly increase cortisol, prolactin, and ACTH — confounding factors in research settings.
Ipamorelin's key research advantage is its high selectivity: it stimulates GH release with minimal effect on cortisol, prolactin, or ACTH at research-relevant doses, making it a cleaner tool for isolating GH-specific effects. This selectivity profile makes ipamorelin particularly valuable in studies where researchers need to attribute observed effects specifically to GH elevation rather than to concurrent stress hormone changes.
The GHSR pathway activated by ipamorelin is distinct from the GHRHR pathway activated by sermorelin and CJC-1295. GHSR activation increases intracellular calcium through Gq protein coupling and phospholipase C activation, while GHRHR activation primarily works through Gs protein coupling and cAMP elevation. This mechanistic distinction means that combining a GHSR agonist (ipamorelin) with a GHRHR agonist (CJC-1295) activates two independent GH-stimulating pathways simultaneously, producing synergistic GH release studied to be significantly greater than either compound alone.
CJC-1295: GHRH Analog with DAC Modification
CJC-1295 is a synthetic GHRH analog with two key modifications: a tetrasubstituted amino acid at position 2 for DPP-4 resistance, and a drug affinity complex (DAC) modification consisting of a maleimidoproprionic acid (MPA) group that enables covalent binding to serum albumin via a Michael addition reaction with the free thiol group of albumin's Cys-34 residue. This albumin binding dramatically extends the half-life of CJC-1295 from approximately 30 minutes (without DAC) to 6–8 days (with DAC).
The extended half-life of CJC-1295 with DAC makes it a useful research tool for studying the effects of sustained, continuous GHRHR stimulation — in contrast to the pulsatile stimulation produced by shorter-acting GHRH analogs. CJC-1295 without DAC (also called Modified GRF 1-29) retains the DPP-4 resistance modification but lacks the albumin-binding group, resulting in a half-life of approximately 30 minutes and a more physiologically pulsatile GH release pattern.
GHRP-6 & MK-677: Additional GHSR Research Tools
GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that was among the first GHSR agonists developed for research use. Unlike ipamorelin, GHRP-6 has broader receptor activity and significantly stimulates cortisol, prolactin, and ACTH in addition to GH — making it useful for research specifically studying the relationship between GH secretion and stress hormone co-activation, but less suitable for studies requiring isolated GH effects.
MK-677 (Ibutamoren) is a non-peptide, orally active GHSR agonist with a half-life of approximately 24 hours. Its oral bioavailability and long duration of action make it a distinctive research tool for studying sustained GHSR activation and its downstream effects on GH pulsatility, IGF-1 levels, sleep architecture (GH is predominantly secreted during slow-wave sleep), and metabolic parameters over extended research periods.
Research Use Disclaimer
All compounds described are sold by Aldera Bio Labs strictly for in-vitro laboratory research by qualified professionals. Not for human or animal consumption. Not FDA-approved. Must be 21+ to purchase.